Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr

Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024

JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24

JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%

Piramal Pharma releases Sustainability Report FY 2023-24

The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence

Chemify gets grant to design and discover new drug leads for Tuberculosis and Malaria

Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults

Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25

Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market

Akums Q1 FY25 revenue up 5.1%

The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually